Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1136/esmoopen-2016-000073 http://scihub22266oqcxt.onion/10.1136/esmoopen-2016-000073 C5070246!5070246!27843627     free     free     free Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       ESMO+Open 2016 ; 1 (4): ä Nephropedia Template TP {{tp|p=27843627|t=2016. Twenty years of anti-HER2 therapy-associated cardiotoxicity |pdf=|usr=}}{{27843627}} gab.com Text Twenty years of anti-HER2 therapy-associated cardiotoxicity JO: ESMO Open http://www.kidney.de/pget.php?&tw=1&pmid=27843627 #FOAvip Over the past 20?years, the prognosis of HER2-positive breast cancer has been transformed by the development of anti-HER2 targeted therapies. In early clinical trials of trastuzumab (ie, the first anti-HER2 agent to be developed) cardiotoxicity became a major concern. In the first published phase 3 trial of trastuzumab, 27% of patients receiving anthracyclines and trastuzumab experienced cardiac events and 16% suffered from severe congestive heart failure. In subsequent trials conducted in advanced and early settings, the incidence of cardiac events was reduced through changes in chemotherapy regimens, more strict patient selection and close cardiac assessment. However, cardiotoxicity remains a significant problem in clinical practice that is likely to increase as new agents are approved and exposure times increase through improved patients' survival. Though numerous trials have led to improved understanding of many aspects of anti-HER2 therapy-related cardiotoxicity, its underlying physiopathology mechanisms are not well understood. The purpose of this article is to provide an in-depth review on anti-HER2 therapy-related cardiotoxicity, including data on both trastuzumab and the recently developed anti-HER2 targeted agents. Twit Text FOAVip Twenty years of anti-HER2 therapy-associated cardiotoxicity ????ESMO Open http://www.kidney.de/pget.php?&tw=1&pmid=27843627 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=27843627 #FOAvip English Wikipedia <ref>{{Cite pmid|27843627}}</ref> Twenty years of anti-HER2 therapy-associated cardiotoxicity #MMPMID27843627 Pondé NF; Lambertini M; de Azambuja E ESMO Open 2016[]; 1 (4): ä PMID27843627show ga Over the past 20?years, the prognosis of HER2-positive breast cancer has been transformed by the development of anti-HER2 targeted therapies. In early clinical trials of trastuzumab (ie, the first anti-HER2 agent to be developed) cardiotoxicity became a major concern. In the first published phase 3 trial of trastuzumab, 27% of patients receiving anthracyclines and trastuzumab experienced cardiac events and 16% suffered from severe congestive heart failure. In subsequent trials conducted in advanced and early settings, the incidence of cardiac events was reduced through changes in chemotherapy regimens, more strict patient selection and close cardiac assessment. However, cardiotoxicity remains a significant problem in clinical practice that is likely to increase as new agents are approved and exposure times increase through improved patients' survival. Though numerous trials have led to improved understanding of many aspects of anti-HER2 therapy-related cardiotoxicity, its underlying physiopathology mechanisms are not well understood. The purpose of this article is to provide an in-depth review on anti-HER2 therapy-related cardiotoxicity, including data on both trastuzumab and the recently developed anti-HER2 targeted agents. äTwenty years of anti-HER2 therapy-associated cardiotoxicity (epmc).pdf DeepDyve Pubget Overpricing